Remagine Labs to Showcase Seizure Patch Innovation at IEC 2025 in Lisbon

Remagine Labs to Present at the 36th International Epilepsy Congress 2025 in Lisbon

Austin, Texas – August 28, 2025 – Remagine Labs, a medical device company developing novel electro-pharmaceutical patches for epilepsy and other neurological disorders, today announced itwill present at the upcoming International Epilepsy Congress (IEC), taking place August 30 –September 3, 2025, in Lisbon, Portugal.

Prof. Stan Skafidas, Co-Founder and Chief Technology Officer, will deliver a platform presentation in the ILAE Neurotechnology Session on Sunday, August 31, 2025, from 2:15 PM to 2:40 PM (Lisbon local time). The talk, titled “Novel Modes of ASM Delivery – The Seizure Patch”, will introduce a wearable iontophoretic device designed to deliver antiseizure medications such as fenfluramine through the skin. Data to be presented include preclinical results demonstrating controlled transdermal delivery, programmable dosing, and simulated plasma concentrations comparable to oral administration.

“Epilepsy patients and their families face real challenges with current oral therapies, including side effects, drug–drug interactions, and adherence,” said Pat Kelly, Co-Founder and CEO of Remagine Labs. “Our goal with The Seizure Patch is to simplify treatment and improve precision by enabling electronic control of medication delivery through the skin.”

Remagine Labs will also highlight its $3M Australian CRC-P grant program supporting preclinical and first-in-human studies, with the goal of initiating clinical trials in 2026.

For more information on Remagine Labs and its upcoming presentation at IEC 2025, please visit www.remaginelabs.com.